Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 16, 2024 04:59 ET | Source: Research and Markets

Acute Lymphocytic Leukemia (ALL) Pipeline Landscape Report 2024: Comprehensive Insights About 250+ Companies and 250+ Pipeline Drugs

Dublin, April 16, 2024 (GLOBE NEWSWIRE) -- The "Acute lymphocytic leukemia (ALL) - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This "Acute...
December 05, 2023 10:48 ET | Source: Research and Markets

Global Acute Myeloid Leukemia (AML) Therapeutics Strategic Research Report 2023: Market to Reach $1.6 Billion by 2030 with Cytarabine Accounting for $571.6 Million

Dublin, Dec. 05, 2023 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Acute...
September 22, 2023 04:28 ET | Source: Research and Markets

Partnerships Drive Innovation in the Leukemia Therapeutics Market: Pfizer Leads with Approval for DAURISMO, Enabling Novel Treatment Possibilities

Dublin, Sept. 22, 2023 (GLOBE NEWSWIRE) -- The "Global Leukemia Therapeutics Market Size, Share & Industry Trends Analysis Report By Drug Class (Targeted Therapy & Immunotherapy and...
May 02, 2023 07:33 ET | Source: Research and Markets

Leukemia Therapeutics Global Market Report 2023: Rises in Product Approvals and Increasing Diagnosis Awareness Drives Growth

Dublin, May 02, 2023 (GLOBE NEWSWIRE) -- The "Leukemia Therapeutics Market by Type, Drug Class, Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been...
February 01, 2023 12:13 ET | Source: Research and Markets

Global Acute Myeloid Leukemia (AML) Therapeutics Market Report 2022 to 2030: Players Include Abbott Laboratories, Boehringer Ingelheim, Cephalon and Eisai

Dublin, Feb. 01, 2023 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia (AML) Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive...
October 17, 2022 04:33 ET | Source: Research and Markets

$1.9 Billion Worldwide Acute Myeloid Leukemia Therapeutics Industry to 2027 - Featuring Abbvie, Amgen, Bristol-Myers Squibb, Celgene and Roche Holding Among Others

Dublin, Oct. 17, 2022 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
December 06, 2021 03:38 ET | Source: Research and Markets

Global Acute Myeloid Leukemia (AML) Therapeutics Market Report 2021: Market to Reach $976.2 Billion by 2026 - Emerging Drug Therapies/Targeted Therapies to Drive Future Growth

Dublin, Dec. 06, 2021 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia (AML) Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering....
August 05, 2021 07:28 ET | Source: Research and Markets

Acute Myeloid Leukemia (AML) Market Insights & Epidemiology Analysis & Forecasts, 2018-2020 & 2021-2030: Major Markets, Marketed Therapies, Emerging Therapies, Case Reports, Patient Journey

Dublin, Aug. 05, 2021 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia (AML)- Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. The...
April 12, 2021 06:48 ET | Source: Research and Markets

Global Acute Myeloid Leukemia (AML) Disease Analysis Report 2021: On Average, it Takes 10.8 Years from Phase I to Approval, Compared to 9.6 Years in the Overall Oncology Space

Dublin, April 12, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Acute Myeloid Leukemia (AML)" report has been added to ResearchAndMarkets.com's offering. AML is a type of heterogeneous...
September 18, 2020 04:53 ET | Source: Research and Markets

Global Acute Myeloid Leukemia (AML) Disease Analysis Report 2020

Dublin, Sept. 18, 2020 (GLOBE NEWSWIRE) -- The "Disease Analysis: Acute Myeloid Leukemia (AML)" drug pipelines has been added to ResearchAndMarkets.com's offering. The publisher estimates that in...

Next Page keyboard_arrow_right